Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Clene (NASDAQ:CLNN), a late clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, will participate in the H.C.

Rhea-AI Summary

Clene (NASDAQ:CLNN), a late clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company, which specializes in developing treatments for ALS and multiple sclerosis, will deliver a virtual presentation available for viewing on September 5, 2025. Management will also host one-on-one investor meetings during the conference. Investors can access the presentation through the company's website or register online for the webcast.

Argus Sep 2 session

+20.11% close to close Open Argus

Details

News Market Reaction – CLNN

On Sep 2, the day this news came out, CLNN closed 20.11% above the previous close.

Data tracked by StockTitan Argus for the Sep 2 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 27^th Annual Global Investment Conference and host 1x1 investor meetings.

Date: September 8-10, 2025
Location: New York City, NY
Format: Virtual Presentation available for viewing on September 5, 2025
1x1 Meetings: Please contact your H.C. Wainwright representative

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Clene (CLNN) presenting at the H.C. Wainwright Conference 2025?

Clene's virtual presentation will be available for viewing on September 5, 2025, with the conference running from September 8-10, 2025 in New York City.

What diseases does Clene (CLNN) focus on treating?

Clene focuses on treating neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

How can investors access Clene's H.C. Wainwright conference presentation?

Investors can access the presentation through the 'Events' section of Clene's website or by registering online for the webcast.

What type of meetings will Clene (CLNN) host at the H.C. Wainwright conference?

Clene will host one-on-one investor meetings during the conference. Interested parties should contact their H.C. Wainwright representative to schedule.